<DOC>
	<DOCNO>NCT01425970</DOCNO>
	<brief_summary>Part A : The purpose study evaluate safety tolerability INX-08189 placebo Peginterferon alfa-2a Ribavirin 12 week treatment Part B : The purpose study evaluate safety tolerability INX-08189 Ribavirin INX-08189 Daclatasvir INX-08189 Daclatasvir Ribavirin</brief_summary>
	<brief_title>Chronically-infected HCV Genotype 2 3 Treatment-naive Subjects : Part A : Safety Efficacy INX-08189 With Peg IFN Alfa-2a Ribavirin . Part B : INX-08189 Interferon Free Treatment With Daclatasvir and/or Ribavirin</brief_title>
	<detailed_description>Data Monitoring Committee appoint Part A Masking : Part A study Double blind Part B Open Label</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Amendment 4 : Genotype 1 , 10 subject site 401 . Males female , 18 65 year age inclusive body mass index ( BMI ) least 18 kg/m2 exceed 36 kg/m2 Diagnosed chronic HCV least 6 month prior Visit 1 medical documentation ( e.g. , prior PCR result , prior liver biopsy , prior genotyping , etc . ) , positive HCV viral load least 50,000 IU/mL Visit 1 ( screen ) measure quantitative PCR Chronic genotype 2 3 HCV infection ( per polymerase chain reaction [ PCR ] methodology ) HCV treatmentnaïve `` treatmentnaïve '' define prior treatment IFN alfa 2a 2b , Pegylated IFN alfa2a , Ribavirin , HCV directacting antiviral drug Liver biopsy consistent chronic HCV infection classification noncirrhotic ( without classification 'transition cirrhosis borderline cirrhosis ' ) judge pathologist ( define Knodell ≤ 3 , Metavir ≤ 2 , Ishak ≤ 4 , Batts &amp; Ludwig ≤ 2 ) within last two year Visit 2 ( biopsy do Visit 1 Visit 2 , within screen period ) Negative urine drug screen drug abuse methadone ( via central labprovided dipstick site ) screening ( Visit 1 ) ( note : subject valid prescription drug abuse [ e.g. , benzodiazepine , opiates ] enrol judgment investigator ) Females negative serum beta human chorionic gonadotropin ( βHCG ) pregnancy test screen negative urine dipstick pregnancy test Study Day 0 ( visit 2 ) Agreement female subject childbearing potential male subject ( surgically sterilize ) practice acceptable method birth control , include least one barrier study least 6 month cessation treatment . Surgical sterilization either female male partner must occur least 6 month prior first dose female must postmenopausal 2 year consider nonchildbearing potential . Acceptable contraceptive method include one following : Oral implantable hormonal contraceptive female partner least 3 month prior first dose Study Drug additional use barrier method , IUD place least 6 month prior first dose additional use barrier method . Acceptable barrier method include either diaphragm spermicide , condom spermicide . ( Note : Abstinence acceptable method birth control , subject indicate sexual inactivity must agree utilize acceptable method birth control event sexual activity ) Willing able complete study visit procedure , able effectively communicate investigator test center personnel Signed informed consent form ( ICF ) execute prior protocol screen assessment Signs symptom decompensated liver disease variceal bleeding , ascites , hepatic encephalopathy , active jaundice define indirect bilirubin &gt; 2 , Alanine transaminase ( ALT ) Aspartate aminotransferase ( AST ) laboratory value ≥ 10 time upper limit normal , evidence decompensated liver disease , hepatocellular carcinoma Chronic liver disease HCV limit Hepatitis B virus ( HBV ) [ positive test hepatitis B surface antigen ( HBsAg ) ] , hemochromatosis , autoimmune hepatitis , alcoholic liver disease nonalcoholic fatty liver disease History liver transplantation Coinfection Human immunodeficiency virus ( HIV ) [ positive test antiHIV Ab ] use didanosine History heart attack , cardiac ischemia , heart disease , clinically symptomatic cardiac abnormality , blood clot , base medical history apparent physical exam QTcF interval Visit 1 great equal 450 m Fridericia 's correction , personal family history Torsades de Pointe History presence sarcoidosis pancreatitis History presence severe pulmonary function impairment include severe ( &gt; GOLD stage III ) chronic obstructive pulmonary obstructive disease , moderate severe asthma Uncontrolled diabetes mellitus evidence HbA1C ≥ 8.5 % screening ( Visit 1 ) Use follow medication concurrently within 30 day prior Screening ( Visit 1 ) associate QT prolongation : macrolides , antiarrhythmic agent , azoles , fluoroquinolones , tricyclic antidepressant ( specifically exclude medication list protocol Section 6.8 ) Use immunosuppressive immunemodulating agent ( include azathioprine , corticosteroid immunosuppressive agent ) presence immunologicallymediated autoimmune disease ( asthma ) history solid organ bone marrow transplantation ( note : inhaled steroid mild/moderate asthma topical steroid minor skin condition allow washout period per Oral ( PO ) /Intramuscular ( IM ) / Intravenous ( IV ) corticosteroid use 8 week ; washout period immunosuppressive determine Medical Monitor ) Use strong CYP3A4inhibiting protease inhibitor ( specifically Atazanavir , Indinavir , Nelfinavir , Saquinavir , Ritonavir ) , strong CYP3A4 inhibitor ( specifically Clarithromycin , Itraconazole , Ketoconazole , Nefazodone , Telithromycin ) , strong CYP3A4 inducer ( specifically Rifampin , Efavirenz , Etravirine , Phenobarbital , Phenytoin , Carbamazepine ) Absolute neutrophil count &lt; 1800 cells/mm3 , platelet count &lt; 130,000 cells/mm3 , hemoglobin &lt; 12 g/dl woman &lt; 13 g/dl men , history anemia , sickle cell anemia , thalassemia ; ( note : baseline value within 5 % minimum qualifying value , one retest allow purpose qualify study ) A history presence abnormal thyroid function adequately control [ define Thyroidstimulating hormone ( TSH ) level less 0.8 x low limit normal ( LLN ) great 1.2 x upper limit normal ( ULN ) ] Creatinine clearance &lt; 50 mL/minute , serum creatinine concentration ≥ 1.5 time ULN , albumin ≤ 3 g/dl Presence history bipolar disorder , schizophrenia , psychosis , unstable psychiatric condition , hospitalization psychiatric condition , suicide attempt . ( Note : Subjects psychiatric condition need adequately treat stable dos appropriate medication least 3 month prior Visit 1 . History suicidal ideation within prior 3 month exclusionary ) Any malignancy within last 5 year treat cervical carcinoma situ treat basal cell carcinoma 20 % risk recurrence within 2 year Alcohol abuse assessment investigator within past 2 year alcohol use pattern interfere study conduct Drug abuse assessment investigator within last six month Pregnancy , current lactation female subject , male subject partner pregnant , females intend become pregnant Major surgery within 30 day prior Visit 1 Participation another clinical trial investigational drug device within 6 month prior Visit 1 unless prior participation involve exposure placebo clear available documentation Donation blood plasma within 30 day prior Visit 1 ( include routine laboratory assessment )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Inhibitex</keyword>
	<keyword>Chronic Hepatitis</keyword>
	<keyword>Hepatitis C Virus</keyword>
</DOC>